BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

  Latest News

Eli Lilly Sells Automated Lab to Arctoris, Platform Relocates to Oxford

by Roman Kasianov   •   Sept. 16, 2024  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

# Contract Research   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

Arctoris, a contract research organization (CRO) specializing in automated drug discovery, has acquired Eli Lilly's Life Sciences Studio laboratory. The acquisition involves relocating the lab's advanced automation platform from San Diego to Arctoris' headquarters in Oxford, UK, effectively doubling the company's laboratory capacity.

#advertisement
How BenchSci’s ASCEND Builds a Map for Biomedical Reasoning

Originally established by Eli Lilly in 2017 as part of a $90 million investment, the Life Sciences Studio was designed to integrate various drug discovery processes into a fully automated platform. The 11,500-square-foot facility combined design, synthesis, purification, analysis, and hypothesis testing, enabling researchers to control experiments remotely via cloud-based software.

With the acquisition, Arctoris adds five automated biochemistry modules, a high-throughput screening module, and an additional automated BSL2 cell biology module to its platform. The company also increases its compound storage capacity to 4 million compounds using automated storage systems and advanced plate formatting technologies.

See also: The CRO Industry in Flux: Navigating Technology, Business Models, and Trends in Pharma R&D Outsourcing

Arctoris utilizes its proprietary automation platform, Ulysses, which combines robotics and data science to accelerate drug discovery across disciplines such as biochemistry, biophysics, and molecular and cellular biology.

By automating experiments, Ulysses is designed to generate high-quality, reproducible data while reducing human error and variability. This approach aims to enable faster decision-making and accelerate the progression of drug candidates from target validation through lead optimization.

Collaborating with biotech firms and pharmaceutical companies, Arctoris supports various stages of drug discovery, including target validation, hit identification, and lead optimization. The company's platform is intended to enhance data quality and reliability, which is crucial for training machine learning models used in computational drug design.

The expanded capabilities from the acquisition are expected to further reduce research timelines and address reproducibility challenges associated with traditional laboratory methods.

Arctoris

Topics: Contract Research   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.